Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON40298Active, not recruiting
Open-label trial of sevoflurane, propofol and remifentanil (4 arms), sponsored by Masimo. Primary endpoints: Predicted propofol and remifentanil plasma and effect-site concentrations, Measured propofol and remifentanil plasma concentrations and 5 more. Started Jan 2014; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON40298.